Terapet

Positron Emission Tomography (PET) enables non-invasive visualization of biological processes for diagnosis, treatment assessment, and drug development.

Nuclyscan is a total-body PET/CT scanner using new detector technology for high-sensitivity, high-resolution imaging.

Terapet will participate in the 4th FLASH Radiotherapy & Particle Therapy Workshop, focusing on advancements in FLASH radiotherapy and particle therapy.

Terapet hosted its first PTCOG61 event, featuring a successful exhibition of its product Qualyscan.

Terapet’s second PTCOG62 event in Singapore showcased Qualyscan, the world’s first end-to-end quality assurance device for particle therapy.

Terapet partnered with Politecnico di Milano to advance research and development in proton therapy solutions.

Read Venture Kick Annual Report: Annual Report 2020

Terapet received CHF 1.53 million in non-dilutive funding to develop its first full-scale prototype for proton therapy.

Terapet seeks motivated professionals to contribute to precision imaging and particle therapy innovation.

Terapet, a CERN spin-off, develops imaging solutions for radiation therapy and nuclear medicine, connecting treatment planning with in vivo verification.

Terapet is preparing for growth in advanced imaging solutions for particle therapy and nuclear medicine, including product development, clinical validation, and international expansion.

Terapet collaborates with clinical centers, research institutions, and industry leaders to advance particle therapy and molecular imaging.

Terapet is located at Rue du Pré-Bouvier 7, 1242 Satigny, Geneva, Switzerland. Contact via info@terapet.ch.

Terapet develops gamma-ray detection systems for treatment verification and clinical imaging in nuclear medicine and particle therapy.